NanoViricides Reports That Its CEO Dr. Seymour Will Be Interviewed about the Evolving Ebola Crisis on Fox Bus. News at 9PM ED...
September 16 2014 - 6:33PM
Business Wire
NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”), a
nanomedicine company developing anti-viral drugs, reported that its
CEO, Eugene Seymour, MD, MPH will be a guest on “The Independents”,
a show on the Fox Business Channel this evening, airing at 9PM
EDT.
He will discuss the current Ebola outbreak and the Company’s
progress in developing an anti-Ebola drug for the treatment of
patients infected with the Ebola virus.
He will also discuss some of the difficulties that could be
encountered in attempts to bring the Ebola epidemic under control.
Dr. Seymour has extensive field experience in the area of
infectious diseases. He has previously worked
on HIV/AIDS in Africa, Eastern Europe and Asia.
Currently, there are no approved drugs or vaccines against
Ebola, although some vaccines as well as some drug candidates have
entered clinical trials. The limitations of vaccines, antibodies,
siRNA and oligonucleotide therapies are well known. A rapidly
evolving virus such as the current Ebola virus can readily mutate
such that these types of strain specific or narrow spectrum drugs
may be rendered ineffective. In light of the paucity of available
countermeasures, recently, the WHO has announced a policy for use
of experimental drugs against Ebola to expedite drug
availability.
NanoViricides, Inc. now has the capability of producing
sufficient quantities of an anti-Ebola drug, after it is developed,
for combating current and future Ebola epidemics. The highly
customizable nanomedicine cGMP capable pilot scale manufacturing
facility in Shelton, CT, will be able to supply all of the
nanoviricides drug candidates in quantities needed for human
clinical trials.
The Company has now developed novel drug candidates against
Ebola that it believes could lead to a successful therapeutic. A
nanoviricide® drug is made up of two components that are chemically
connected together: a virus-binding ligand that mimics the native
receptor on the host cell to which the virus binds, and a backbone
polymer that makes the nanoviricide “look like” the host cell
surface to the virus. There have been significant developments in
the elucidation of the important cell surface receptors and
attachment factors of Ebola virus recently. With this new structure
based information, the Company has been able to redesign its
anti-Ebola ligands using the scientific in silico drug design
methodology.
The Honorable US President, Barak Obama has declared today that
the World needs America to help defeat this epidemic Ebola virus,
in a speech delivered at the CDC. “Faced with this outbreak, the
world is looking to us, the United States, and it’s a
responsibility that we embrace,” said the President. The U.S. has
committed $500Million in defense spending on this “war on Ebola”,
named Operation United Assistance, reported Time magazine online
(http://time.com/3387646/obama-on-ebola-the-world-is-looking-to-us/).
The current outbreak in Africa has unequivocally demonstrated
the need for an effective, broad-spectrum, anti-Ebola therapeutic
from which the mutating virus would not escape.
As of 10 September 2014, the World Health Organization (WHO) and
the United States Centers for Disease Control and Prevention (CDC)
reported a total of 4,846 suspected cases and 2,375 deaths,
according to Wikipedia
(http://en.wikipedia.org/wiki/Ebola_virus_epidemic_in_West_Africa).
WHO has reported an overall measure of case fatality rate estimate
of 52%, considerably lower than that reported from previous
outbreaks. However, the actual case fatality rate based on
following infected patients in a limited region was found to be
about 77%. Unfortunately, this Ebola outbreak has continued to
expand at an exponential rate in spite of significant efforts to
contain it.
The Company is in negotiations with several parties regarding
testing the new nanoviricide drug candidates against Ebola in the
required high safety environments, i.e. BSL-4 facilities.
Because of the magnitude of the current outbreak, the Company
restarted its EbolaCide development program. It had previously
developed anti-Ebola drug candidates that demonstrated the validity
and potential of the Company’s approach, based on cell culture and
animal testing conducted at US Army Medical Research Institute of
Infectious Diseases (USAMRIID) in a BSL-4 facility. The Company had
to de-prioritize this development in order to focus on the
development of its lead drug candidate, Injectable FluCide™, for
treatment of hospitalized patients with influenza. The Company has
recently reported that it has restarted its anti-Ebola/Marburg drug
program, in consideration of the severe public health impact of an
Ebola virus epidemic.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating
special purpose nanomaterials for viral therapy. The Company's
novel nanoviricide® class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle
them. The Company is developing drugs against a number of viral
diseases including H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
that are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although
it is not possible to predict or identify all such factors, they
may include the following: demonstration and proof of principle in
pre-clinical trials that a nanoviricide is safe and effective;
successful development of our product candidates; our ability to
seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products.
NanoViricides, Inc.Amanda Schuon, 310-550-7200info@nanoviricides.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Sep 2024 to Oct 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Oct 2023 to Oct 2024